The United States Federal Trade Commission approved, Wednesday, Israeli generic-drug giant Teva's $40.5 billion acquisition of the generics business of Ireland's Allergan PLC. The deal was conditioned upon Teva’s divestiture of 75 drugs to rivals in order to preserve competition in markets where Teva and Allergan currently compete or would have likely competed if not for the merger.
FTC approval was the last hurdle for the deal, which is now expected to close next week.